A qualitative approach to assess the opinion of physicians about the challenges and prospects of pharmacogenomic testing implementation in clinical practice in Greece.
Attitudes
Future recommendations
Intentions to adopt
Perceptions
Pharmacogenomics
Physicians
Qualitative research
Semi-structured interview
Journal
Human genomics
ISSN: 1479-7364
Titre abrégé: Hum Genomics
Pays: England
ID NLM: 101202210
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
03
06
2024
accepted:
12
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
epublish
Résumé
Pharmacogenomics (PGx) constitutes an important part of personalized medicine and has several clinical applications. PGx role in clinical practice is known, however, it has not been widely adopted yet. In this study, we aim to investigate the perspectives of Greek physicians regarding the implementation of PGx testing in clinical practice and the key issues associated with it. Fourteen interviews were conducted with physicians of various specialties for which PGx applications are available. A semi-structured interview guide was utilized based on the Consolidated Framework for Implementation Research (CFIR) context and the Diffusion of Innovation model. Transcripts were coded independently and compared by two members of the research team. Descriptive statistics were generated using Microsoft Excel. Six main themes emerged: awareness and use of PGx testing; source of information; key stakeholders of the PGx supply chain, their interactions and change agents; clinical benefit and significance of PGx testing; barriers and lack of reimbursement; and recommendations to boost the PGx adoption rate. Most respondents were aware of PGx applications, but only three had already recommended PGx testing. Peer-reviewed journals along with clinical guidelines were regarded as the most used source of information while stakeholders of the PGx supply chain were discussed. PGx was considered that promote patient-centered care, enhance medication clinical effectiveness, decrease the risk of side effects, and reduce healthcare costs. Lack of reimbursement, scarcity of resources, and high PGx cost were the foremost barriers affecting PGx adoption. It was concluded that if case PGx testing is reimbursed and physicians' training is reinforced, PGx implementation will be boosted and improved shortly.
Sections du résumé
BACKGROUND
BACKGROUND
Pharmacogenomics (PGx) constitutes an important part of personalized medicine and has several clinical applications. PGx role in clinical practice is known, however, it has not been widely adopted yet. In this study, we aim to investigate the perspectives of Greek physicians regarding the implementation of PGx testing in clinical practice and the key issues associated with it.
METHODS
METHODS
Fourteen interviews were conducted with physicians of various specialties for which PGx applications are available. A semi-structured interview guide was utilized based on the Consolidated Framework for Implementation Research (CFIR) context and the Diffusion of Innovation model. Transcripts were coded independently and compared by two members of the research team. Descriptive statistics were generated using Microsoft Excel.
RESULTS
RESULTS
Six main themes emerged: awareness and use of PGx testing; source of information; key stakeholders of the PGx supply chain, their interactions and change agents; clinical benefit and significance of PGx testing; barriers and lack of reimbursement; and recommendations to boost the PGx adoption rate. Most respondents were aware of PGx applications, but only three had already recommended PGx testing. Peer-reviewed journals along with clinical guidelines were regarded as the most used source of information while stakeholders of the PGx supply chain were discussed. PGx was considered that promote patient-centered care, enhance medication clinical effectiveness, decrease the risk of side effects, and reduce healthcare costs. Lack of reimbursement, scarcity of resources, and high PGx cost were the foremost barriers affecting PGx adoption.
CONCLUSIONS
CONCLUSIONS
It was concluded that if case PGx testing is reimbursed and physicians' training is reinforced, PGx implementation will be boosted and improved shortly.
Identifiants
pubmed: 39030587
doi: 10.1186/s40246-024-00648-y
pii: 10.1186/s40246-024-00648-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82Subventions
Organisme : Research Committee of the University of Patras
ID : 918/12.06.2024
Informations de copyright
© 2024. The Author(s).
Références
Gladding PA. Clinical applications of pharmacogenetics: Present and near future. Cleve Clin J Med. 2013;80(8):477–82.
doi: 10.3949/ccjm.80a.12111
pubmed: 23908102
Klein ME, Parvez MM, Shin JG. Clinical implementation of Pharmacogenomics for Personalized Precision Medicine: barriers and solutions. J Pharm Sci. 2017;106(9):2368–79.
doi: 10.1016/j.xphs.2017.04.051
pubmed: 28619604
Saunders H, Harris D, Chirilă RM. Pharmacogenomics: introduction and use in clinical practice. Rom J Intern Med. 2020;58(2):69–74.
pubmed: 32074077
Shin J, Kayser SR, Langaee TY. Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm. 2009;66(7):625–37.
doi: 10.2146/ajhp080170
pubmed: 19299369
Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15(3):201–10.
doi: 10.1038/tpj.2014.86
pubmed: 25707393
Swen JJ, Van Der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–56.
doi: 10.1016/S0140-6736(22)01841-4
pubmed: 36739136
Abou Diwan E, Zeitoun RI, Abou Haidar L, Cascorbi I, Khoueiry Zgheib N. Implementation and obstacles of pharmacogenetics in clinical practice: an international survey. Br J Clin Pharmacol. 2019;85(9):2076–88.
doi: 10.1111/bcp.13999
pubmed: 31141189
pmcid: 6710530
Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, Van Schaik RHN, Schwab M, et al. Global Pharmacogenomics within Precision Medicine: challenges and opportunities. Clin Pharmacol Ther. 2020;107(1):57–61.
doi: 10.1002/cpt.1664
pubmed: 31696505
Koufaki MI, Karamperis K, Vitsa P, Vasileiou K, Patrinos GP, Mitropoulou C. Adoption of pharmacogenomic testing: a marketing perspective. Front Pharmacol. 2021;12:724311.
doi: 10.3389/fphar.2021.724311
pubmed: 34603034
pmcid: 8484788
Deininger KM, Page RL, Lee YM, Kauffman YS, Johnson SG, Oreschak K, et al. Non-interventional cardiologists’ perspectives on the role of pharmacogenomic testing in Cardiovascular Medicine. Pers Med. 2019;16(2):123–32.
doi: 10.2217/pme-2018-0099
Deininger KM, Tsunoda SM, Hirsch JD, Anderson H, Lee YM, McIlvennan CK, et al. National survey of physicians’ perspectives on pharmacogenetic testing in solid organ transplantation. Clin Transpl. 2020;34(10):e14037.
doi: 10.1111/ctr.14037
Haga SB, Tindall G, O’Daniel JM. Professional perspectives about Pharmacogenetic Testing and Managing Ancillary findings. Genet Test Mol Biomark. 2012;16(1):21–4.
doi: 10.1089/gtmb.2011.0045
Lemke AA, Hutten Selkirk CG, Glaser NS, Sereika AW, Wake DT, Hulick PJ, et al. Primary care physician experiences with Integrated Pharmacogenomic Testing in a Community Health System. Pers Med. 2017;14(5):389–400.
doi: 10.2217/pme-2017-0036
Carroll JC, Makuwaza T, Manca DP, Sopcak N, Permaul JA, O’Brien MA, et al. Primary care providers’ experiences with and perceptions of personalized genomic medicine. Can Fam Physician Med Fam Can. 2016;62(10):e626–35.
Jia T, Wu C, Hu X, Li S, Zhang X, Cai Y, et al. Physicians’ knowledge, attitude, and experience of pharmacogenomic testing in China. J Pers Med. 2022;12(12):2021.
doi: 10.3390/jpm12122021
pubmed: 36556242
pmcid: 9783535
Ahmed NJ, Alrawili AS, Alkhawaja FZ. Knowledge and awareness on Personalized Medicine amongst Health Care specialists and University Students in Health Colleges in Saudi Arabia. J Pharm Res Int. 2020;177–83.
Cain M, Mittman R. Diffusion of innovation in health care. Oakland, Calif.: California Healthcare Foundation; 2002.
Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated Consolidated Framework for Implementation Research based on user feedback. Implement Sci. 2022;17(1):75.
doi: 10.1186/s13012-022-01245-0
pubmed: 36309746
pmcid: 9617234
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50.
doi: 10.1186/1748-5908-4-50
pubmed: 19664226
pmcid: 2736161
Ha VTD, Frizzo-Barker J, Chow-White P. Adopting clinical genomics: a systematic review of genomic literacy among physicians in cancer care. BMC Med Genomics. 2018;11(1):18.
doi: 10.1186/s12920-018-0337-y
pubmed: 29433521
pmcid: 5810117
Li C, Su X, Sun Q, Huang Y. Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis. Pharmacogenomics J. 2023;23(5):127–33.
doi: 10.1038/s41397-023-00306-x
pubmed: 37142641
Wondrasek A, Fryza A, Aziz MA, Leong C, Kowalec K, Maruf AA. Knowledge, perceptions, and attitudes toward pharmacogenomics among pharmacists and pharmacy students: a systematic review. Health Sci Rep. 2024;7(1):e1844.
doi: 10.1002/hsr2.1844
pubmed: 38274140
pmcid: 10809028
Creswell JW, Poth CN. Qualitative inquiry & research design: choosing among five approaches. Fourth edition. Los Angeles: SAGE; 2018.
Miles MB, Huberman AM, Saldaña J. Qualitative data analysis: a methods sourcebook. Third edition. Thousand Oaks, Califorinia: SAGE Publications, Inc; 2014. 381 p.
Pope C, Mays N, editors. Qualitative research in health care. Fourth edition. Hoboken: Wiley-Blackwell; 2020. 1 p.
Mitropoulou C, Mai Y, Van Schaik RH, Vozikis A, Patrinos GP. Stakeholder Analysis in Pharmacogenomics and genomic medicine in Greece. Public Health Genomics. 2014;17(5–6):280–6.
doi: 10.1159/000365896
pubmed: 25228172
Rahma AT, Elbarazi I, Ali BR, Patrinos GP, Ahmed LA, Al-Maskari F. Stakeholders’ interest and attitudes toward genomic medicine and pharmacogenomics implementation in the United Arab Emirates: a qualitative study. Public Health Genomics. 2021;24(3–4):99–109.
doi: 10.1159/000513753
pubmed: 33730737
Truong TM, Apfelbaum JL, Schierer E, Danahey K, Borden BA, Karrison T, et al. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022;32(3):79–86.
doi: 10.1097/FPC.0000000000000455
pubmed: 34570085
pmcid: 8940738
Shue SA, Rowe E, Bell LA, Damush T, DeLong A, Gowan T, et al. Pharmacogenomics Implementation across Multiple clinic settings: a qualitative evaluation. Pharmacogenomics. 2023;24(17):881–93.
doi: 10.2217/pgs-2023-0179
pubmed: 37975236
Vest BM, Wray LO, Brady LA, Thase ME, Beehler GP, Chapman SR, et al. Primary care and mental health providers’ perceptions of implementation of pharmacogenetics testing for depression prescribing. BMC Psychiatry. 2020;20(1):518.
doi: 10.1186/s12888-020-02919-z
pubmed: 33115428
pmcid: 7594429
Almeida BC, Gonçalves ED, De Sousa MH, Osis MJMD, De Brito Mota MJB, Planello AC. Perception and knowledge of pharmacogenetics among Brazilian psychiatrists. Psychiatry Res. 2021;306:114238.
doi: 10.1016/j.psychres.2021.114238
pubmed: 34656849
Lau-Min KS, Varughese LA, Nelson MN, Cambareri C, Reddy NJ, Oyer RA, et al. Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. BMC Cancer. 2022;22(1):47.
doi: 10.1186/s12885-022-09171-6
pubmed: 34996412
pmcid: 8742388
Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry. eBioMedicine. 2024;101:105009.
doi: 10.1016/j.ebiom.2024.105009
pubmed: 38364700
pmcid: 10879811
Unertl KM, Jaffa H, Field JR, Price L, Peterson JF. Clinician perspectives on using pharmacogenomics in clinical practice. Pers Med. 2015;12(4):339–47.
doi: 10.2217/PME.15.10
Koufaki MI, Makrygianni D, Patrinos GP, Vasileiou KZ. How do Pharmacy Students make Career choices in Genomics? Gender and other Key determinants of Pharmacy Senior Students’ intentions to pursue postgraduate training in Pharmacogenomics. OMICS J Integr Biol. 2023;27(10):474–82.
doi: 10.1089/omi.2023.0153
Schwartz EJ, Issa AM. The role of hospital pharmacists in the adoption and use of Pharmacogenomics and Precision Medicine. Pers Med. 2017;14(1):27–35.
doi: 10.2217/pme-2016-0063